Navigation Links
Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
Date:5/13/2009

SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the Leerink Swann Oncology Roundtable Conference on Wednesday, May 20, at 2:00 p.m. Eastern Time in New York.

Dr. McMahon's corporate presentation will include a discussion about the clinical development program for the Company's lead product candidate, picoplatin. In addition, Dr. McMahon will participate in an expert panel discussion on the same day at 8:10 a.m. Eastern Time entitled "New Developments in Solid Tumors, Focusing on GU and GI Cancers."

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metasta
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
2. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
4. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
5. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
6. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
7. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 12 to take part in the first half of “Integrative Biotechnology,” an applied ... partnership established in summer 2014, this course combines students from both universities and ...
(Date:6/30/2015)... -- NASA astronaut Kjell Lindgren , who is making final ... to the International Space Station , will be available ... Tuesday, July 7. Lindgren will participate from the ... . The interviews will be preceded at 7:30 a.m. ... To schedule an interview, media must contact ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... Coach Tom Shaw has Trained the Last 7 Super Bowl MVP,s; ... 1 Overall NFL Draft Picks and 18 Starting ... Quarterbacks in the NFL Last Season, BASKING ... Biotechnologies,Group, Inc. (OTC Bulletin Board: MBTG), announced today that SURGEX(TM) is,currently ...
... pest insect known as bollworm is the first to evolve ... insecticide called Bt, according to a new research report. ... more than a dozen crop fields in Mississippi and Arkansas ... evolution in action," said lead researcher Bruce Tabashnik. "This is ...
... 7 Falling stock prices,devaluing dollar, soaring gas prices, ... of the symptoms of the recession hitting the U.S. ... have a deeper impact,on pharma and biotech companies as ... pressures and decreasing numbers of newly,approved therapies. Given the ...
Cached Biology Technology:Tom Shaw's NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen 2Tom Shaw's NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen 3First documented case of pest resistance to biotech cotton 2First documented case of pest resistance to biotech cotton 3Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study 2
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... first time, UK scientists have reported direct evidence that taking ... of cancer. The results were reported at the 35th ... Milan, Italy. The link between smoking and cancer has ... the Cancer Research UK Institute of Cancer Studies, Birmingham, who ...
... cancer patients seem to live longer and experience delays in ... molecule called MET is added to treatment with erlotinib, the ... David Spigel, Director of lung cancer research for the Sarah ... at the 35th Congress of the European Society for Medical ...
... Researchers at the University of Illinois at Chicago College of ... drug resistance is ramped up in unusual types of breast ... study is published in the Oct. 8 issue of the ... a paper of the week. Approximately 70 percent of ...
Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2Clue to unusual drug-resistant breast cancers found 2
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Recombinant Feline IL-12/IL-23 p40...
Request Info...
Recombinant Equine IL-6...
Biology Products: